Archive for January, 2014

“Guardian of the Genome” Therapies – A New Golden Age for Cancer R&D?

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Last April, I wrote here about the paradox of cancer research funding where over $100 billion in R&D funding for genomic targeting of cancer tumors has yielded only modest gains for […]


Drug Patent Expirations for December 24 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

BiologicPatentWatch -- biologic drug patent expiration information

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for December 24 2013

Tradename Applicant Generic Name Patent
Expiration
ANTHELIOS SX

Loreal Usa

avobenzone; ecamsule; octocrylene

Dec 24, 2013
VIOXX

Merck

rofecoxib

Dec 24, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Drug Patent Expirations for December 23 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

BiologicPatentWatch -- biologic drug patent expiration information

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for December 23 2013

Tradename Applicant Generic Name Patent
Expiration
DDAVP

Sanofi Aventis Us

desmopressin acetate

Dec 23, 2013
DDAVP
(NEEDS NO REFRIGERATION)

Sanofi Aventis Us

desmopressin acetate

Dec 23, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Journal of Commercial Biotechnology new issue available

The Journal of Commercial Biotechnology is published by BiotechBlog’s producer, thinkBiotech. Journal of Commercial Biotechnology Volume 20, Number 1 Russia-Focused Venture Capital Supports In-Bound Technology Transfer and Company Building: An Analysis of Investment Trends and Outcomes John M. Garvey, Shann Kerner, Axel Tillmann, Dmitry Kuzmin This paper analyzes the approaches taken by the Russian government […]


Mergers and acquisitions: A consideration of the drivers and hurdles

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Mergers and acquisitions: A consideration of the drivers and hurdles
Go to paperABSTRACT: Mergers and acquisitions (M&A) are increasingly being include…


A biological battlefield: The potential applications of using remote sensing technology and biomarker organisms for identifying, tracking, and differentiating persons of interest within an area of operations

Since World War II, the majority of American wartime engagements have been characterized by a series of low-intensity, asymmetric conflicts. These conflicts have increased the importance of understanding the dynamics of individual actors within complex battlespaces which in turn has led U.S. military commanders, intelligence professionals, and wartime decision makers to seek a variety of means for identifying, tracking, and differentiating persons of interest. From the jungles of Vietnam to the mountains of Afghanistan, the process of understanding the movements and activities of hostile actors has become paramount to successful military targeting and combat operations. Over the last 50 years, the military and intelligence communities have developed a plethora of technologies capable of accomplishing this task to include overhead satellites, infrared imaging, unmanned aerial vehicles (UAV), advanced biometrics, and host of other personnel identifying and tracking technologies. While these technologies have closed the gap in enabling U.S. military and intelligence professionals to understand the human aspect of the battlespace, there are still significant challenges in uniquely identifying the movements and activities of specific persons or groups of persons.

            Given the above outlined challenge of understanding the battlespace, this article will explore an alternative means of identifying and uniquely tracking individuals. Specifically, this article will explore the combined use of remote sensing technologies and genetically engineered biomarkers in order to uniquely identify, track, and differentiate persons of interest. Such a combination of two disparate technical fields would be technologically challenging both within the biological and remote imaging scientific fields, thus emphasizing the paramount importance of combining biological markers with distinct signatures that are detectable by specific and technologically matching visualization means. In addition to discussing the technical challenges associated with such a combination of technologies, this article will also discuss both the potential military benefits and negative implications this process could have in ethical, legal, and diplomatic terms. At the conclusion of this article, the reader should have a fundamental understanding of how remote sensing technologies and biomarkers can be combined to better understand the battlespace as well as the possible implications of this technological paring. 


A Social Media Manifesto

The role of marketing communications is to advance the bottom line and the public good – and not necessarily in that order. Giving back is an integral part of the New Normal. And there has never been a better tool to accomplish this mission than social media.

But healthcare marketing –and particularly of the regulated variety –is between a rock and a hard place. On the one hand, marketers understand the importance and opportunity in social media. It’s where the people are. It’s where the action is. But then there are all those pesky regulatory concerns.

As Walter O’Malley –the man who moved the Brooklyn Dodgers to Los Angeles once commented, “The future is just one damn thing after another.”


Biotechnology Venture Investing and Neurodegenerative Medicine: Promise of New Approaches to Cure an Ailing Model

Neurodegenerative diseases are one of the leading public health challenges of the next 50 years. Pharmaceutical therapies have traditionally targeted the later stages of neurodegenerative diseases; however, this strategy – as the recent failures of clinical trials for Alzheimer’s drugs have highlighted – has been unsuccessful. Venture capital has underperformed as well during this time, as many new companies have been unable to maintain growth once they reach the public market and have produced less than desirable returns. As a result, venture capitalists have opted for later-stage financing. Nevertheless, new technologies are being developed to answer the question of how to best address neurodegeneration. New tools of detection will allow for much earlier diagnosis and a much greater chance of discovering and applying effective treatments. Realizing that genetic knowledge is insufficient to produce innovative treatments for neurodegenerative diseases, scientists have begun to apply the genetic knowledge attained towards a future of individualized treatments. As these new tools of detection converge with an increased ability to create very precise individual solutions, the risk of successful future investments should come down and provide the potential for outsized returns that have traditionally governed the venture capital financial model.


Russia-Focused Venture Capital Supports In-Bound Technology Transfer and Company Building: An Analysis of Investment Trends and Outcomes

This paper analyzes the approaches taken by the Russian government to promote innovation in the biotechnology sector within the country.  Russia is economically strong, currently with a trade surplus, and the country is investing broadly in initiatives that have resulted in in-bound technology transfer, as well as an expansion of the private sector.  These initiatives include government venture capital and investment funds, as well as physical technology “incubator” centers.  The result has been an increase in the number of clinical-stage biotechnology companies operating in Russia, as well as an increase in the number of pharmaceutical candidates undergoing trials in the country.  The biotechnology “boom” has also resulted in an increase in the number of early-stage companies.  This paper investigates current deal and investment trends from the funds that are the principal supporters of biotechnology companies in Russia.